Analysts Set Immunocore Holdings plc (NASDAQ:IMCR) Price Target at $79.82

Immunocore Holdings plc (NASDAQ:IMCR) has been given a consensus recommendation of “Moderate Buy” by the fourteen brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have issued a buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $75.17.

IMCR has been the subject of a number of research reports. Guggenheim cut shares of Immunocore from a “buy” rating to a “neutral” rating in a report on Monday, October 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunocore in a research report on Monday, September 9th. Barclays cut their price target on Immunocore from $92.00 to $66.00 and set an “overweight” rating on the stock in a report on Friday, August 9th. UBS Group began coverage on Immunocore in a report on Thursday, October 24th. They set a “sell” rating and a $24.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of Immunocore in a research report on Thursday, October 24th.

Immunocore Trading Up 1.6 %

Shares of NASDAQ IMCR opened at $33.33 on Tuesday. The firm has a 50 day moving average price of $33.25 and a two-hundred day moving average price of $40.72. The stock has a market cap of $1.67 billion, a P/E ratio of -27.32 and a beta of 0.72. Immunocore has a 52-week low of $29.72 and a 52-week high of $76.98. The company has a debt-to-equity ratio of 1.31, a quick ratio of 5.15 and a current ratio of 5.17.

Immunocore (NASDAQ:IMCR) last released its earnings results on Thursday, August 8th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.25. The business had revenue of $75.40 million during the quarter, compared to the consensus estimate of $74.58 million. Immunocore had a negative net margin of 19.16% and a negative return on equity of 14.68%. The company’s revenue for the quarter was up 26.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.37) EPS. As a group, equities analysts forecast that Immunocore will post -1.68 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in IMCR. SG Americas Securities LLC lifted its position in shares of Immunocore by 1,867.3% during the 2nd quarter. SG Americas Securities LLC now owns 160,358 shares of the company’s stock worth $5,435,000 after buying an additional 152,207 shares in the last quarter. Candriam S.C.A. boosted its position in Immunocore by 65.8% in the second quarter. Candriam S.C.A. now owns 313,423 shares of the company’s stock worth $10,621,000 after purchasing an additional 124,417 shares during the last quarter. Frazier Life Sciences Management L.P. bought a new position in Immunocore in the 2nd quarter valued at $3,686,000. Janus Henderson Group PLC increased its position in shares of Immunocore by 45.8% during the 1st quarter. Janus Henderson Group PLC now owns 257,080 shares of the company’s stock valued at $16,711,000 after purchasing an additional 80,748 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in shares of Immunocore by 16.2% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 397,463 shares of the company’s stock worth $13,470,000 after purchasing an additional 55,463 shares during the period. 84.50% of the stock is owned by institutional investors.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.